Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Half the time, same effect? new study tests shorter light therapy for scalp lesions

NCT ID NCT07290959

Disease control Sponsor: San Salvatore Hospital of L'Aquila Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a 1-hour indoor light treatment works as well as the standard 2-hour version for actinic keratosis (scaly sun-damaged spots) on the scalp. Fifty-five adults with multiple lesions received both durations on different sides of their scalp. Researchers measured how many spots cleared up after 3 and 6 months, along with pain and skin reactions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
methyl aminolevulinate (MAL) cream with white LED light
What this could lead to
If successful, this could make indoor daylight PDT more convenient by halving the treatment time, potentially improving patient comfort and clinic efficiency.
What could go wrong
This is a small, completed study with only 55 participants, so results may not apply to everyone. Shorter exposure might be less effective for some lesions, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

55 people

The number who actually took part.

Started

Jan 2025

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (age \>50 years) with multiple AK located on the scalp (at least 5 Olsen grade I or II AK in two symmetrical areas) and diagnosed according to their typical clinical dermoscopic appearance * Subject must be able to understand and be willing to adhere to all protocol requirements and voluntarily sign and date an informed consent Exclusion Criteria: * previous treatment for AK within 6 months; * status of congenital, infectious, or iatrogenic immunodepression; * known cutaneous photosensitivity; * known hypersensitivity to any ingredient of Metvix® 160 135 mg/g cream (Galderma SA, Lausanne, Switzerland).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Actinic keratosis (AK) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

actinic keratosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Actinic keratosis (AK)

Contacts and locations

Locations

  • Ospedale San Salvatore

    L’Aquila, 67100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.